Chinese COVID-19 drugs are expected to be launched soon
- Engineered Soybeans with Pig Protein: A Promising Alternative or Pandora’s Dish?
- Severe Fever with Thrombocytopenia Syndrome (SFTS): A Tick-Borne Threat with High Mortality
- Why Isolating Bananas Extends Their Shelf Life?
- This common vitamin benefits the brain and prevents cognitive decline
- New report reveals Nestlé adding sugar to infant formula sold in poor countries
- Did Cloud Seeding Unleash a Deluge in Dubai?
Chinese COVID-19 drugs are expected to be launched soon.
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Chinese COVID-19 drugs are expected to be launched soon.
The latest news shows that China’s COVID-19 specific drugs finally have a “timetable”, and one of the antibody combination drugs is expected to be approved for conditional listing before the end of the year at the earliest.
According to statistics, there are currently six specific drugs for COVID-19 developed in China. Among them, two effective neutralizing antibody drugs BRII-196 and BRII-198 jointly developed and screened by Tsinghua University, Shenzhen Third People’s Hospital and Tengsheng Huachuang have participated in the treatment of more than 700 patients in China.
The R&D team has submitted the conditional listing application materials to the State Food and Drug Administration on October 9, and is expected to be approved for conditional listing before the end of December.
Professor Zhang Linqi of Tsinghua University: Hundreds of antibodies isolated from the blood of convalescent patients with COVID-19 have screened two antibodies with the highest activity and strong complementarity. In clinical trials conducted at home and abroad, they have shown that they can reduce severe illness and mortality by 78 % Excellent results.
At the same time, the neutralizing antibody DXP604, jointly developed by Peking University’s Xie Xiaoliang team and Danxu Biotechnology, was used as a “sympathetic drug” in Beijing Ditan Hospital when no other drugs were available. After the drug, some patients have recovered and discharged.
In addition, the new generation of androgen receptor antagonist “Prokalutamide” under development by the pioneering pharmaceutical industry has been authorized for emergency use in Paraguay. Three clinical trials conducted in Brazil initially showed that “procrudamide” can Reduce the risk of death for severely ill patients by 78%.
According to the relevant person in charge, the current research and development of effective drugs for the new coronavirus is mainly focused on three technical routes of blocking the virus from entering cells, inhibiting virus replication, and regulating the human immune system. China has already deployed these technical routes.
Chinese COVID-19 drugs are expected to be launched soon.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
